Resverlogix Corp 뉴스 - RVX | 주식 토론토 증권거래소

RESVERLOGIX ENTERS INTO A COOPERATION AGREEMENT WITH THE SUPREME COUNCIL OF THE ARAB-AFRICAN ECONOMY TO SUPPORT THE DEVELOPMENT OF APABETALONE FOR COVID-19 PATIENTS

This initiative will provide the necessary investments to advance first-in-class drug - apabetalone for the potential treatment of COVID-19 within...

RESVERLOGIX ENTERS INTO A COOPERATION AGREEMENT WITH THE SUPREME COUNCIL OF THE ARAB-AFRICAN ECONOMY TO SUPPORT THE DEVELOPMENT OF APABETALONE FOR COVID-19 PATIENTS

This initiative will provide the necessary investments to advance first-in-class drug - apabetalone for the potential treatment of COVID-19 within...

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

CALGARY, Alberta, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX:...

Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone

CALGARY, Alberta, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:...

Resverlogix to Participate in Leading Scientific Conferences

Presentations will Showcase Research by Resverlogix Scientists, Advancing our Understanding of Epigenetics in...

Resverlogix to Present at Upcoming Conferences

CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX:...

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company...

Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus

Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe...

Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study

Apabetalone, a First-in-Class Epigenetic Therapeutic Candidate, Met Key Endpoint of Lowering Pulmonary Vascular...

Resverlogix Announces Management Change

CALGARY, Alberta, July 06, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metasta...

CALGARY, Alberta, June 24, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”), a...

Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders

CALGARY, Alberta, June 22, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation...

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone f...

CALGARY, Alberta and CHICAGO, June 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX...

Resverlogix Announces US$6 Million Debenture Financing

CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:...

Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company...

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Resverlogix Corp (RVX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

RVX 뉴스

RESVERLOGIX ENTERS INTO A COOPERATION AGREEMENT WITH THE SUPREME COUNCIL OF THE ARAB-AFRICAN ECONOMY TO SUPPORT THE DEVELOPMENT OF APABETALONE FOR COVID-19 PATIENTS

RESVERLOGIX ENTERS INTO A COOPERATION AGREEMENT WITH THE SUPREME COUNCIL OF THE ARAB-AFRICAN ECONOMY TO SUPPORT THE DEVELOPMENT OF APABETALONE FOR COVID-19 PATIENTS

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone

Resverlogix to Participate in Leading Scientific Conferences

Resverlogix to Present at Upcoming Conferences

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus

Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study

Resverlogix Announces Management Change

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metasta...

Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone f...

Resverlogix Announces US$6 Million Debenture Financing

Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

RVX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Resverlogix Corp (RVX) 뉴스

Resverlogix Corp (RVX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

RVX 뉴스

RESVERLOGIX ENTERS INTO A COOPERATION AGREEMENT WITH THE SUPREME COUNCIL OF THE ARAB-AFRICAN ECONOMY TO SUPPORT THE DEVELOPMENT OF APABETALONE FOR COVID-19 PATIENTS

RESVERLOGIX ENTERS INTO A COOPERATION AGREEMENT WITH THE SUPREME COUNCIL OF THE ARAB-AFRICAN ECONOMY TO SUPPORT THE DEVELOPMENT OF APABETALONE FOR COVID-19 PATIENTS

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone

Resverlogix to Participate in Leading Scientific Conferences

Resverlogix to Present at Upcoming Conferences

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus

Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study

Resverlogix Announces Management Change

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metasta...

Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone f...

Resverlogix Announces US$6 Million Debenture Financing

Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

RVX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기